Investment analysts have recently revised their earnings predictions for Bausch Health Companies Inc. (NYSE:BHC), indicating a more optimistic outlook for the company in the fiscal year 2024. According to a report from Zacks Research, the projected earnings per share (EPS) for Bausch Health has been increased to $3.59, a slight uptick from the previous estimate of $3.58. This forecast aligns closely with the consensus estimate which stands at $3.60 per share for the current fiscal year.
In addition to the FY2024 earnings forecast, Zacks Research has also provided estimates for future quarters, predicting that Bausch Health will report earnings of $1.32 per share for the fourth quarter of 2025, $4.21 per share for the entire fiscal year 2025, and $1.15 per share for the second quarter of 2026.
Other financial analysts have also weighed in on Bausch Health’s performance. StockNews.com recently upgraded the company’s shares from a “hold” rating to a “buy” rating, reflecting growing confidence in the stock’s potential. Piper Sandler has raised its price target for Bausch Health shares from $7.00 to $9.00, while maintaining a “neutral” rating in their analysis dated April 29th. Conversely, Royal Bank of Canada has adjusted its target price downwards from $12.00 to $11.00, categorizing the stock as a “sector perform.”
Raymond James has also initiated coverage on Bausch Health, issuing a “market perform” rating and setting a price target at $8.00. The overall sentiment among analysts indicates that three have rated the stock as a hold, while two have given it a buy rating. According to MarketBeat, the average rating for Bausch Health Companies is currently “Hold,” with an average price target of $10.50.
On the trading front, Bausch Health Companies shares opened at $7.57 on Wednesday. Over the past year, the stock has experienced fluctuations, with a 12-month low of $6.05 and a high of $11.46. The company boasts a market capitalization of approximately $2.74 billion, with a price-to-earnings (P/E) ratio of -6.10 and a beta of 0.77. The stock’s 50-day moving average is currently $6.79, while its 200-day moving average stands at $8.06.
Bausch Health Companies recently released its quarterly earnings data on May 2nd. The report revealed an EPS of $0.59 for the quarter, which fell short of analysts’ consensus estimates of $0.75 by $0.16. The company reported a negative return on equity of 2,370.91% and a negative net margin of 5.07%. In terms of revenue, Bausch Health generated $2.15 billion during the quarter, slightly below the consensus estimate of $2.18 billion.
As analysts continue to evaluate Bausch Health’s performance and future prospects, the stock remains a focal point for investors looking to navigate the complexities of the healthcare market. The adjustments in earnings estimates and ratings reflect a dynamic environment for the company as it seeks to enhance its market position.
